Literature DB >> 1732285

Aggressive fibromatosis.

B A Alman1, M J Goldberg, S P Naber, T Galanopoulous, H N Antoniades, H J Wolfe.   

Abstract

Ten patients with aggressive fibromatosis of the extremities were prospectively followed for 2-6 years. Results of treatment methods were compared. Five patients underwent three-dimensional imaging with and without intravenous contrast, and the images were compared with the anatomic extent of the resected lesion. Pathologic specimens and control tissue were tested for the presence of estrogen and progesterone receptors and for expression of the c-sis oncogene and platelet-derived growth factor (PDGF), potent mitogens for fibrocytes. Wider surgical resection resulted in a lower recurrence rate, but current chemotherapeutic agents were not effective in eradicating the tumors. Intravenous contrast enhanced the lesions. Two thirds of the tumors tested had estrogen or progesterone receptors. All tumors tested had inappropriate expression of c-sis and PDGF. This inappropriate expression may be responsible for the underlying pathobiology and deregulation of control of growth in aggressive fibromatosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732285

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  3 in total

1.  Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors).

Authors:  B A Alman; C Li; M E Pajerski; S Diaz-Cano; H J Wolfe
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Immunohistochemical analysis of desmoid tumours.

Authors:  A Leithner; M Gapp; R Radl; A Pascher; P Krippl; K Leithner; R Windhager; A Beham
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

3.  A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders.

Authors:  Raymond Poon; Helen Hong; Xin Wei; James Pan; Benjamin A Alman
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.